Brodalumab receives positive CHMP opinion for the treatment of adult patients with moderate-to-severe plaque psoriasis

Click here to view online. Add this email to your safelist.

19 May 2017

AstraZeneca today announced that its partner LEO Pharma has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending the approval of brodalumab for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.